Multispray technology for studying biomolecular interactions
Active Project Grant Awarded Last action
- Award ID
- R44GM161156
- Recipient
-
Newomics Inc. UEI LMKSNZ862R36
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,000,000
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date 58% complete
- Place of performance
- Berkeley, CA 94710, USA
Award details come from USAspending.gov.
Description
- Abstract
- Proteome reflects physiology and pathology of a person therefore proteomics is a powerful tool for early disease diagnosis, drug discovery, and therapeutic response monitoring. Mass spectrometry (MS) measures the mass- to-charge ratio of charged species and has become the enabling technology for proteomics. One of the most exciting developments in mass spectrometry in recent years is native spray mass spectrometry for studying biomolecular interactions under native or native-like physiological conditions. This was mainly due to the dramatic improvement in resolution and sensitivity of the new classes of high-resolution mass spectrometers. On the other hand, the mass spectrometry front-end solutions including sample processing and LC chromatography have not kept pace with the mass spectrometry back-end revolutions. Major technological advances are needed to achieve high sensitivity, robustness, throughput, and automation for diverse LC-MS analysis of biologically relevant samples. In this sbir direct phase II project, newomics proposes to further develop and commercialize its differentiated, vendor-agnostic, uniesi system with M3 emitters and MEA chips, as an integrated imaging-mass spec front-end platform, for native spray mass spectrometry. We will validate the performance of the platform for native MS studies of biomolecular interactions predicted by alphafold 3 and demonstrate its utilities in studying conformational changes and ligand binding under native conditions. Once commercialized, our uniesi platform will facilitate high-throughput and high-sensitivity top- down proteomics and native mass spectrometry, for studying biomolecular interactions and discovery of new drugs and druggable targets, thereby contributing to precision medicine.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,000,000 | |
| Original award | $1,000,000 |
Quick answers
Who received award R44GM161156?
R44GM161156 was awarded to Newomics Inc. by National Institute of General Medical Sciences (National Institutes of Health) on September 1, 2025.
How much is award R44GM161156 worth?
$2,000,000 has been obligated on R44GM161156.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award